Table 1.

Active-controlled trials

Ref	Validity score	Comparison	Surgery	Sponsorship
	random blinding dropouts	(number of patients in brackets)
[28]	1/1/0	1) Ondansetron 8 mg iv (50) 2) Droperidol 1.25 mg iv (50)	Not reported
[29]	2/2/1	1) Ondansetron 0.1 mg/kg iv (16) 2) Droperidol 20 μg/kg iv (13)	Extraabdominal
[32]	2/2/0	1) Droperidol 1.25 mg iv (27) 2) Metoclopramide 10 mg iv (25) 3) Propofol 10 mg iv (26)	Mixed
[36]	1/1/0	1) Ondansetron 4 mg iv (380) 2) Metoclopramide 10 mg iv (366)	Not reported	Glaxo
[37]	1/1/0	1) Droperidol 20 μg/kg iv (40) 2) Granisetron 40 μg/kg iv (40) 3) Metoclopramide 0.2 mg/kg iv (40)	Laparoscopic cholecystectomy
[38]	1/1/0	1) Droperidol 20 μg/kg iv (40) 2) Granisetron 40 μg/kg iv (40) 3) Metoclopramide 0.2 mg/kg iv (40)	Major gynecological
[39]	1/1/1	1) Alizapride 100 mg iv (24) 2) Droperidol 1 mg iv (25) 3) Ondansetron 8 mg iv (25)	Gynecological	Glaxo